Cyrielle Caussy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cyrielle Caussy has a total of 452 co-authors. Here are the top co-authors by number of shared publications:
Emmanuel Disse
Hospices Civils de Lyon, Département Endocrinologie, Diabète et Nutrition, Hôpital Lyon Sud, 69495, Pierre-Bénite, France; Univ Lyon, CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, 69495, Pierre-Bénite, France
8 shared publicationsBruno Vergès
6 shared publicationsLaurent Castera
6 shared publicationsAlexia Rouland
4 shared publicationsBertrand Cariou
4 shared publicationsElisabetta Bugianesi
Global NASH/MASH Council Washington DC USA
4 shared publications
Latest Publications
- 24 September 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 84 (5) , E70-E71
Erratum: Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study
Was not provided for this article.
- 24 September 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 84 (5) , E70-E71
Erratum: Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study
Was not provided for this article.
- 18 August 2026
- Published by Wiley in Liver International
- Vol. 46 (9) , e70806
Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma
The Paris International Liver Meeting (January 19–21, 2026) brought together leading hepatology experts to discuss transformative advances in chronic liver disease management. The meeting highlighted pivotal developments reflecting the field's evolution from disease characterisation toward precision, mechanism‐based therapeutics. Metabolic dysfunction‐associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‐associated steatohepatitis (MASH), were highlighted, marking the transition to an era of approved disease‐modifying therapies. Resmetirom and semaglutide are now approved for MASH with F2–F3 fibrosis, with a robust pipeline generating anti‐fibrotic signals through FGF21 analogs, pan‐peroxisome proliferator‐activated receptor (PPAR) agonists, and incretin‐based dual and triple agonists. Non‐invasive tests have evolved beyond their original diagnostic role to enable prognostic stratification, screening of at‐risk populations, treatment selection, and monitoring of therapeutic response. This evolution is not limited to MASLD, but extends to other chronic liver diseases, including primary biliary cholangitis (PBC) and portal hypertension, as highlighted by the recommendations of the Baveno Consensus Workshops. Hepatitis B and D are moving toward functional cure strategies, with simplified HBV treatment algorithms based on fibrosis and viral load, supported by biomarkers for risk stratification and safe treatment discontinuation. In parallel, HDV management is transitioning from a severe disease to one with emerging suppressive and potential curative l through bulevirtide and novel HBsAg‐targeting and RNA‐silencing therapies, respectively. Management of PBC has advanced with novel PPAR agonists that improve cholestatic biochemistry and pruritus, supported by individualised risk stratification. However, significant treatment gaps persist, with fewer than half of eligible PBC patients receiving second‐line therapy, and fatigue remains a major unmet clinical need. Furthermore, effective pharmacotherapies for primary sclerosing cholangitis (PSC) remain a major challenge, and no approved disease‐modifying treatments are currently available. Finally, for patients with hepatocellular carcinoma (HCC), immunotherapy combinations can achieve unprecedented long‐term survival in selected populations of patients. Collectively, these advances define a new era of hepatology centered on precision medicine, earlier intervention, and mechanism‐driven therapeutic strategies.
- 18 August 2026
- Published by Wiley in Liver International
- Vol. 46 (9) , e70806
Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma
The Paris International Liver Meeting (January 19–21, 2026) brought together leading hepatology experts to discuss transformative advances in chronic liver disease management. The meeting highlighted pivotal developments reflecting the field's evolution from disease characterisation toward precision, mechanism‐based therapeutics. Metabolic dysfunction‐associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‐associated steatohepatitis (MASH), were highlighted, marking the transition to an era of approved disease‐modifying therapies. Resmetirom and semaglutide are now approved for MASH with F2–F3 fibrosis, with a robust pipeline generating anti‐fibrotic signals through FGF21 analogs, pan‐peroxisome proliferator‐activated receptor (PPAR) agonists, and incretin‐based dual and triple agonists. Non‐invasive tests have evolved beyond their original diagnostic role to enable prognostic stratification, screening of at‐risk populations, treatment selection, and monitoring of therapeutic response. This evolution is not limited to MASLD, but extends to other chronic liver diseases, including primary biliary cholangitis (PBC) and portal hypertension, as highlighted by the recommendations of the Baveno Consensus Workshops. Hepatitis B and D are moving toward functional cure strategies, with simplified HBV treatment algorithms based on fibrosis and viral load, supported by biomarkers for risk stratification and safe treatment discontinuation. In parallel, HDV management is transitioning from a severe disease to one with emerging suppressive and potential curative l through bulevirtide and novel HBsAg‐targeting and RNA‐silencing therapies, respectively. Management of PBC has advanced with novel PPAR agonists that improve cholestatic biochemistry and pruritus, supported by individualised risk stratification. However, significant treatment gaps persist, with fewer than half of eligible PBC patients receiving second‐line therapy, and fatigue remains a major unmet clinical need. Furthermore, effective pharmacotherapies for primary sclerosing cholangitis (PSC) remain a major challenge, and no approved disease‐modifying treatments are currently available. Finally, for patients with hepatocellular carcinoma (HCC), immunotherapy combinations can achieve unprecedented long‐term survival in selected populations of patients. Collectively, these advances define a new era of hepatology centered on precision medicine, earlier intervention, and mechanism‐driven therapeutic strategies.
- Open Access
- 1 August 2026
- Published by Springer Nature in Diabetologia
- Vol. 69 (11) , 3175-3195
Is MASLD an independent risk factor for micro- and macrovascular complications of diabetes? A critical reappraisal and future directions
- 1 August 2026
- Published by Springer Nature in Diabetologia
- Vol. 69 (11) , 3175-3195
Open AccessIs MASLD an independent risk factor for micro- and macrovascular complications of diabetes? A critical reappraisal and future directions
- Open Access
- 23 July 2026
- Published by Elsevier in Médecine des Maladies Métaboliques
- Vol. 20 (5) , 468-489
Prise en charge des patients atteints de diabète de type 2 et de MASLD : synthèse et position commune selon l’AFEF et la SFD
- 23 July 2026
- Published by Elsevier in Médecine des Maladies Métaboliques
- Vol. 20 (5) , 468-489
Open AccessPrise en charge des patients atteints de diabète de type 2 et de MASLD : synthèse et position commune selon l’AFEF et la SFD
- Open Access
- 11 May 2026
- Published by Elsevier in Diabetes & Metabolism
- Vol. 52 (4) , 101766
Risk stratification of MASLD-related advanced fibrosis using a novel point-of-care device: the Hepatoscope
- 11 May 2026
- Published by Elsevier in Diabetes & Metabolism
- Vol. 52 (4) , 101766
Open AccessRisk stratification of MASLD-related advanced fibrosis using a novel point-of-care device: the Hepatoscope
- 26 February 2026
- Published by Elsevier in Clinics in Liver Disease
- Vol. 30 (2) , 343-358
Algorithms for Risk Stratification in Patients with Metabolic Dysfunction-Associated Steatohepatitis
- 26 February 2026
- Published by Elsevier in Clinics in Liver Disease
- Vol. 30 (2) , 343-358
Algorithms for Risk Stratification in Patients with Metabolic Dysfunction-Associated Steatohepatitis
- Open Access
- 25 February 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (9) , 101798
Steatotic liver disease trajectory: A holistic EASL guidance on the multidisciplinary approach to screening and patient management☆
- 25 February 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (9) , 101798
Open AccessSteatotic liver disease trajectory: A holistic EASL guidance on the multidisciplinary approach to screening and patient management☆
- Top Cited PapersOpen Access
- 17 February 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (3) , 661-678
Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction–associated steatotic liver disease
Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as NAFLD, is increasingly recognized as a prevalent global burden. Type 2 diabetes mellitus (T2DM), another important metabolic disease, is considered a major contributor to the development of MASLD. MASLD and T2DM have a strong association with each other due to shared pathogenic mechanisms. The co-existence of the 2 diseases increases the risk of liver-related adverse outcomes and imposes a heavier burden on extrahepatic outcomes, representing a substantial public health issue. Effective assessment and management of T2DM combined with MASLD necessitate a multidisciplinary approach. The emergence of numerous RCTs has shed light on the treatment of T2DM combined with MASLD. This review uncovers the epidemiology of the intertwined T2DM and MASLD, offers insights into the evaluation of hepatic fibrosis in patients with T2DM, glucose monitoring in the MASLD population, and provides comprehensive co-management strategies for addressing both diseases.
- 17 February 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (3) , 661-678
Top Cited PapersOpen AccessEpidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction–associated steatotic liver disease
Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as NAFLD, is increasingly recognized as a prevalent global burden. Type 2 diabetes mellitus (T2DM), another important metabolic disease, is considered a major contributor to the development of MASLD. MASLD and T2DM have a strong association with each other due to shared pathogenic mechanisms. The co-existence of the 2 diseases increases the risk of liver-related adverse outcomes and imposes a heavier burden on extrahepatic outcomes, representing a substantial public health issue. Effective assessment and management of T2DM combined with MASLD necessitate a multidisciplinary approach. The emergence of numerous RCTs has shed light on the treatment of T2DM combined with MASLD. This review uncovers the epidemiology of the intertwined T2DM and MASLD, offers insights into the evaluation of hepatic fibrosis in patients with T2DM, glucose monitoring in the MASLD population, and provides comprehensive co-management strategies for addressing both diseases.
- Open Access
- 30 January 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (4) , 101749
Management of obesity in advanced chronic liver disease
- 30 January 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (4) , 101749
Open AccessManagement of obesity in advanced chronic liver disease
- Open Access
- 15 October 2025
- Published by Elsevier in Diabetes & Metabolism
- Vol. 51 (6) , 101709
Management of patients with type 2 diabetes and MASLD: An overview and joint statement
- 15 October 2025
- Published by Elsevier in Diabetes & Metabolism
- Vol. 51 (6) , 101709
Open AccessManagement of patients with type 2 diabetes and MASLD: An overview and joint statement